Stockscreener 앱 받기
4.31
1.41%
0.06
시간 외 거래:
4.00
-0.31
-7.19%
전일 마감가:
$4.25
열려 있는:
$4.26
하루 거래량:
627.00K
Relative Volume:
1.91
시가총액:
$265.39M
수익:
$45.15M
순이익/손실:
$-39.23M
주가수익비율:
-2.3565
EPS:
-1.829
순현금흐름:
$-18.93M
1주 성능:
-13.80%
1개월 성능:
-12.93%
6개월 성능:
+7.75%
1년 성능:
-7.31%
1일 변동 폭
$4.245
$4.50
1주일 범위
$4.08
$5.30
52주 변동 폭
$2.20
$7.95
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
명칭
Trisalus Life Sciences Inc
전화
415 336 8917
주소
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
4.31 | 267.23M | 45.15M | -39.23M | -18.93M | -1.829 |
ABT
Abbott Laboratories
|
98.83 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.29 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.39 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.65 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.32 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-13 | 개시 | Lake Street | Buy |
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-11-11 | 개시 | ROTH MKM | Buy |
| 2024-10-25 | 개시 | Northland Capital | Outperform |
| 2024-09-16 | 개시 | Oppenheimer | Outperform |
| 2024-05-30 | 개시 | Canaccord Genuity | Buy |
모두보기
Trisalus Life Sciences Inc 주식(TLSI)의 최신 뉴스
FDA Clears TriNav Advance for Expanded Liver Embolization Access - CancerNetwork
TriSalus Life Sciences Shares Rise After Receiving FDA Clearance for TriNav Advance - marketscreener.com
TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support - TradingView
TriSalus Life Sciences Price Target Raised to $12.00/Share From $11.00 by HC Wainwright & Co. - Moomoo
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday - Benzinga
TriSalus Life Sciences Shares Rise 15.6% After FDA Clearance for TriNav Advance - Yahoo Finance
H.C. Wainwright raises TriSalus stock price target on FDA approval By Investing.com - Investing.com Australia
H.C. Wainwright raises TriSalus stock price target on FDA approval - Investing.com
TLSI Looks 31.8% Overvalued on GF Value™ After FDA Nod for TriNa - GuruFocus
HC Wainwright & Co. maintains Buy rating on TriSalus Life Sciences, $12 price target - TradingView
Why is TriSalus Life Sciences stock surging today? By Investing.com - Investing.com Canada
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization - BioSpace
TriSalus Life shares surge 29% on FDA device clearance By Investing.com - Investing.com South Africa
Trisalus Life Sciences Receives FDA Clearance For Trinav Advance - TradingView
TriSalus receives FDA clearance for TriNav Advance device By Investing.com - Investing.com Australia
TriSalus Gains FDA Clearance for TriNav Advance Device - TipRanks
TriSalus receives FDA clearance for TriNav Advance device - Investing.com
TLSI: Innovative tumor therapy delivery, rapid growth, and new product launches drive future outlook - TradingView
TriSalus Life Sciences, Inc. Stock Price Prediction: Today, Tomorrow, Next Week (TLSI) - Traders Union
This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
TriSalus Life Sciences (TLSI) Climbs 1.55% as Support Holds Above $4.99Wyckoff Distribution - vinanet.vn
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference - Business Wire
TriSalus Life Sciences (TLSI) Slips 2% as Shares Test Key $4.59 Support LevelKey Reversal Day - dars.gov.et
TriSalus (TLSI) Results Review: The Bottom-Line Figure Trails Its Comparison in the Available Record; Share Response: Shares Move 3.04% Lower in the Latest SessionWeak Earnings Momentum - vinanet.vn
TriSalus (TLSI) Market: Falls 2.18% to $5.16 on the Day; Technical Setup: the Near-Term Reference Band Stretches From $4.90 to $5.42 on the DayETF NAV Deviation - vinanet.vn
TriSalus (TLSI) Latest: Finishes 1.90% Lower at $5.17 at the Close; Next Test: the Near-Term Reference Band Stretches From $4.91 to $5.43Arms Index - dars.gov.et
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates - Eastern Progress
TriSalus (TLSI) Latest Quarter: The Bottom-Line Figure Trails Its Comparison for This Review; Price Move: Shares Finish 2.47% Up in the Current UpdateSegment Revenue Breakdown - vinanet.vn
TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference - MarketBeat
TriSalus Life Sciences (NASDAQ:TLSI) Cut to "Sell" at Wall Street Zen - MarketBeat
TriSalus Life Sciences Warrant (TLSIW) Plunges 55%: Critical Support Test at $0.53AAII Bullish - vinanet.vn
CCORF Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
TriSalus Life Sciences Inc (TLSI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Trisalus Life Sciences at Canaccord Genuity: growth bets build By Investing.com - Investing.com Nigeria
Trisalus Life Sciences at Canaccord Genuity: growth bets build - Investing.com
TriSalus Life Sciences (TLSI) Advances 2.87% as Shares Hold Above $5.45 SupportETH Profile - dars.gov.et
Maxim Group Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Raises Target Price to $14 - Moomoo
TLSI Q2 2026 Earnings: EPS Misses Slightly as Liver-Tumor Focus ContinuesHealthcare Earnings Report - dars.gov.et
TriSalus Life Sciences (TLSI) Dips 4.3% to $5.37 as Shares Approach Key Support ZoneHigh Yield Stocks - careplusvn.com
TriSalus Life Sciences earnings missed by $0.01, revenue topped estimates - Investing.com Canada
TriSalus Life Sciences (TLSI) Stock Surges As Losses Deepen Behind Strong Margins - Sahm
Securities Fraud Investigation Into TriSalus Life Sciences Inc - The National Law Review
TriSalus Life Sciences, Inc. (TLSI) stock price, news, quote and history - Yahoo Finance UK
TriSalus Life Sciences (NASDAQ:TLSI) Posts Quarterly Earnings Results, Meets Expectations - MarketBeat
TriSalus Life Sciences, Inc. Revenue Breakdown – NASDAQ:TLSIW - TradingView
TriSalus Life Sciences Q2 Earnings Call Highlights - marketbeat.com
Price to earnings forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSIW - TradingView
TriSalus Life Sciences Warrant (TLSIW) Slumps 24% to $1.26 as Sellers Dominate the TapeLeveraged ETF Flow - careplusvn.com
TriSalus Life Sciences Inc (TLSI) (Q2 2026) Earnings Call Highlights: New CMS G-code Expands ... - Yahoo Finance
Earnings call transcript: TriSalus tops Q2 revenue forecast, stock slips after hours - Investing.com
Price to sales forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSIW - TradingView
Trisalus Life Sciences Inc (TLSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Trisalus Life Sciences Inc 주식 (TLSI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Wahlstrom Mats | Director |
May 15 '26 |
Buy |
2.53 |
60,000 |
151,800 |
147,555 |
| Stansky Michael P | Director |
May 15 '26 |
Buy |
2.50 |
410,000 |
1,025,000 |
1,240,722 |
| Stansky Michael P | Director |
May 15 '26 |
Buy |
2.50 |
200,000 |
500,000 |
399,698 |
| Szela Mary T | CEO and President |
May 15 '26 |
Buy |
2.59 |
39,682 |
102,776 |
1,065,215 |
| Patience David | Chief Financial Officer |
May 15 '26 |
Buy |
2.43 |
7,100 |
17,253 |
275,757 |
| Gordon Gary B. | Director |
May 15 '26 |
Buy |
2.46 |
10,000 |
24,600 |
72,510 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 12 '26 |
Sale |
4.09 |
1,772 |
7,247 |
97,637 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 11 '26 |
Sale |
4.13 |
1,162 |
4,799 |
99,409 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 16 '26 |
Sale |
4.12 |
273 |
1,125 |
97,364 |
| Cox Bryan F. | Chief of Research |
Mar 12 '26 |
Sale |
4.09 |
1,467 |
6,000 |
163,994 |
2.75%
자본화:
|
볼륨(24시간):